The event highlighted the development of highly selective, pan-mutant PI3Kα allosteric inhibitors for cancer and vascular anomalies, with two lead candidates advancing toward IND in 1H 2027. KOLs emphasized the differentiated biology, clinical potential, and strategic focus on minimizing toxicity and maximizing efficacy.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.